Physician profile
James E Powers
NPI 1548317555
$2,253.37
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $357 · 2021: $336 · 2022: $285 · 2023: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $885.11 | 2019-2023 | Clareon, Argos, Hydrus Microstent |
| Abbvie INC. | $312.03 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $155.98 | 2019-2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $144.57 | 2019 | |
| Sight Sciences, INC. | $118.62 | 2020-2023 | Tearcare System |
| Johnson & Johnson Vision Care, INC. | $102.22 | 2019 | |
| Allergan, INC. | $99.01 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $93.88 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $90.44 | 2019-2021 | |
| Rxsight INC | $78.39 | 2022 | |
| Carl Zeiss Meditec, INC. | $43.65 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32.74 | 2023 | Acthar |
| Bausch & Lomb Americas INC. | $24.77 | 2022 | |
| Dompe US, INC. | $21.92 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.34 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $15.45 | 2021 | |
| Oyster Point Pharma, INC. | $15.25 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.